Genaera today reported that development partner MedImmune, Inc. presented interim Phase 2a data on MEDI-528 at The American College of Chest Physicians meeting held October 25-30 in Philadelphia, Pennsylvania
Plymouth, PA, USA | October 29, 2008 | Genaera Corporation (NASDAQ: GENR) today reported that development partner MedImmune, Inc. presented interim Phase 2a data on MEDI-528, its monoclonal antibody (MAb) targeting interleukin-9 (IL-9) in adults with mild, persistent asthma, at The American College of Chest Physicians meeting held October 25-30 in Philadelphia, Pennsylvania.
The presentation, entitled “Multiple Subcutaneous Doses of MEDI-528, A Monoclonal Antibody Against Interleukin-9 in Mild and Moderate Asthmatics,” reported the absence of serious, dose-limiting adverse events in the study and concluded that the data demonstrate an acceptable safety profile for multiple subcutaneous doses of MEDI-528.
About IL-9
IL-9 is one of at least 29 naturally occurring interleukins in the human body. Overexpression of IL-9 in animal models has been shown to result in many features of asthma, including increased airway inflammation and hyperreactivity. Blocking the actions of IL-9 has been shown to reduce the airway inflammation and increased airway inflammation and increased airway hyperresponsiveness seen in animal models of asthma. MedImmune is conducting research to evaluate the potential to use MAbs targeting IL-9 to treat or prevent symptomatic, moderate-to-severe, persistent asthma.
About Genaera
Genaera Corporation is developing trodusquemine (MSI-1436) for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma. For further information, please see our website at http://www.genaera.com.
SOURCE: Genaera Corporation
Post Views: 45
Genaera today reported that development partner MedImmune, Inc. presented interim Phase 2a data on MEDI-528 at The American College of Chest Physicians meeting held October 25-30 in Philadelphia, Pennsylvania
Plymouth, PA, USA | October 29, 2008 | Genaera Corporation (NASDAQ: GENR) today reported that development partner MedImmune, Inc. presented interim Phase 2a data on MEDI-528, its monoclonal antibody (MAb) targeting interleukin-9 (IL-9) in adults with mild, persistent asthma, at The American College of Chest Physicians meeting held October 25-30 in Philadelphia, Pennsylvania.
The presentation, entitled “Multiple Subcutaneous Doses of MEDI-528, A Monoclonal Antibody Against Interleukin-9 in Mild and Moderate Asthmatics,” reported the absence of serious, dose-limiting adverse events in the study and concluded that the data demonstrate an acceptable safety profile for multiple subcutaneous doses of MEDI-528.
About IL-9
IL-9 is one of at least 29 naturally occurring interleukins in the human body. Overexpression of IL-9 in animal models has been shown to result in many features of asthma, including increased airway inflammation and hyperreactivity. Blocking the actions of IL-9 has been shown to reduce the airway inflammation and increased airway inflammation and increased airway hyperresponsiveness seen in animal models of asthma. MedImmune is conducting research to evaluate the potential to use MAbs targeting IL-9 to treat or prevent symptomatic, moderate-to-severe, persistent asthma.
About Genaera
Genaera Corporation is developing trodusquemine (MSI-1436) for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma. For further information, please see our website at http://www.genaera.com.
SOURCE: Genaera Corporation
Post Views: 45
